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Abstract
Background: Neogenin is expressed in cap cells that have been suggested to be mammary stem
or precursor cells. Neogenin is known to play an important role in mammary morphogenesis;
however its relationship to tumorigenesis remains to be elucidated.
Methods: To compare the expression levels of neogenin in cells with different tumorigenicity, the
expression levels in M13SV1, M13SV1R2 and M13SV1R2N1 cells, which are immortalized
derivatives of type I human breast epithelial cel l s ,  w e r e  e v a l u a t e d .  T h e n  w e  m e a s u r e d  t h e
expression level of neogenin in paired normal and cancer tissues from eight breast cancer patients.
Tissue array analysis was performed for 54 human breast tissue samples with different histology,
and the results were divided into four categories (none, weak, moderate, strong) by a single well-
trained blinded pathologist and statistically analyzed.
Results: The nontumorigenic M13SV1 cells and normal tissues showed stronger expression of
neogenin than the M13SV1R2N1 cells and the paired cancer tissues. In the tissue array, all (8/8) of
the normal breast tissues showed strong neogenin expression, while 93.5% (43/46) of breast cancer
tissues had either no expression or only moderate levels of neogenin expression. There was a
significant difference, in the expression level of neogenin, in comparisons between normal and
infiltrating ductal carcinoma (p < 0.001).
Conclusion: Neogenin may play a role in mammary carcinogenesis as well as morphogenesis, and
the expression may be inversely correlated with mammary carcinogenicity. The value of neogenin
as a potential prognostic factor needs further evaluation.
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Background
Neogenin, a member of the DCC (Deleted in Colorectal
Cancer) receptor group, encodes a 1461 amino acid pro-
tein and has similar structure to DCC with 50.2% amino
acid identity [1]. Neogenin is one of two groups of netrin-
1 receptors [1,2]. Netrin-1 and its receptor groups were
initially known to induce neurons and axons to target cer-
tain areas during neurogenesis [3]. Netrin-1 and neogenin
do not only regulate axonal guidance but also play an
important role in epithelial morphogenesis [4]. Neogenin
is a cell adhesion molecule, and is expressed in a variety of
developing tissues, such as the gastrointestinal tract of
chickens [5], as well as on the surface of growing neurons
[6].
Neogenin has been found to be expressed in cap cells at
the terminal end buds of breast tissue. Cap cells have been
suggested to be mammary stem or precursor cells located
in the terminal ductal lobular units of the breast [7,8].
Recent data show that netrin-1 and its receptor neogenin
provide an adhesive function during mammary gland
morphogenesis; the binding of netrin-1 and neogenin sta-
bilize the cap cell layer and prevent the influx of cap cells
into the prelumenal compartment; this keeps the cap cells
in their initial location [9]. The relationship between the
expression of neogenin and the tumorigenicity of breast
cancer has not been studied to date.
Kao  et al. reported on obtaining two types of human
breast epithelial cells (HBECs) in a breast tissue specimen
from reduction mammoplasty [10]. Type I HBECs are
known as potent breast stem cell candidates; they can dif-
ferentiate into type II HBECs, and form budding/ductal
organoids in Matrigel. It is also reported that type I HBECs
have luminal epithelial cell markers, and stem cell charac-
teristics, and that type II HBECs show basal epithelial phe-
notypes [11,12]. Nontumorigenic M13SV1 cells are
immortalized cells obtained from the transfection of type
I HBECs with simian virus 40 large T antigens. M13SV1R2
cells, obtained after x-ray irradiation (two doses of 2 Gy 8
days apart) of M13SV1 cells, express weak tumorigenicity
when they are injected into athymic nude mice. The
highly tumorigenic M13SV1R2N1 cells result from trans-
duction of the rat neu  oncogene into M13SV1R2 cells
[11,13].
We hypothesized that neogenin might be related to mam-
mary carcinogenesis. Therefore, we evaluated expression
levels of neogenin in the M13SV1 cell line series
(M13SV1, M13SV1R2, and M13SV1R2N1), the immortal-
ized tumorigenic derivatives from type I HBECs, to com-
pare the expression of neogenin in cells with different
tumorigenicity. Then, we investigated neogenin expres-
sion in paired normal and cancer tissues from eight
patients with infiltrating ductal cancer. Finally, to identify
the pattern of neogenin expression on the basis of differ-
ent histology, we performed tissue array analysis of 54 dif-
ferent human breast tissue samples.
Methods
Cells, cell culture and tissues
The M13SV1, M13SV1R2 and M13SV1R2N1 cells were
cultured in MSU-1 medium, with 10% fetal bovine serum,
containing 100 units of penicillin and 100 µg of strepto-
mycin/ml, in a humidified incubator at 37°C with 5%
CO2 [13].
To determine the expression levels of neogenin, in paired
normal and cancer tissues, from the same patients, we
selected paired specimens from eight patients and stored
the samples in a liquid nitrogen tank. All of the patients
had the diagnosis of an infiltrating ductal carcinoma. Nor-
mal tissues were sampled and were obtained from sites
more than 5 cm away from the tumor margin of the can-
cer. All of the tissues were obtained and stored with the
consent of each patient. The tissues to be used for the tis-
sue array were stored in paraffin-embedded blocks.
Western blot analysis
The M13SV1, M13SV1R2 and M13SV1R2N1 cells were
lysed in 20 mM HEPES (pH 7.2), 150 mM NaCl, 1% Tri-
ton X-100, 2% cholic acid, 1 mM EDTA, 1 mM EGTA, 0.1
mM DTT, 10 µg/ml leupetin, 10 µg/ml aprotinine and 1
mM phenylmetylsulfonyl fluoride (PMSF). Protein con-
tent (25 µg) was determined by the bicinchoninic acid
(BCA) protein assay with bovine serum albumin as a
standard. Cell lysates were released by heating samples at
95°C for 10 minutes in Laemmli cooking buffer and then
separated by SDS (sodium dodecylsuldate)-polyacryla-
mide gel electrophoresis. Samples were transferred onto
nitrocellulose filters and incubated separately with pri-
mary antibodies for two hours. Immunocomplexes were
visualized using the peroxidase conjugated goat anti-rab-
bit IgG antibody. Detection was performed with the ECL
Plex fluorescent Western blotting system (Amersham,
Buckinghamshire, UK). The paired cancer and normal tis-
sues from eight patients were treated in the same way. We
have examined the expression of neogenin with 1:200
diluted anti-neogenin rabbit IgG polyclonal antibody
(#sc-15337, Santa Cruz Biotechnology, California) as a
primary antibody, and 1:5000 diluted horseradish perox-
idase conjugated goat anti-rabbit IgG antibody (#sc-2004,
Santa Cruz Biotechnology, California) as a secondary
antibody.
Tissue array
Tissue array analysis was performed to examine the
expression of neogenin in a variety of tissue types under
the same conditions. We tested the tissues from the fol-
lowing sources: 8 normal, 31 infiltrating ductal carcino-BMC Cancer 2005, 5:154 http://www.biomedcentral.com/1471-2407/5/154
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mas (IDC), 1 ductal carcinoma in situ (DCIS), 9
metastatic lymph nodes from breast cancer, and 5 other
types of breast cancer cases (3 cases of invasive lobular car-
cinoma (ILC), one medullary carcinoma and one signet
ring cell carcinoma). Tissues were embedded in paraffin;
4-µm sections, stained with hematoxylin and eosin
(H&E), were obtained to identify morphologically repre-
sentative areas of the specimen from which the core biop-
sies were taken. We marked the sampling site, on the
corresponding blocks, with H&E stained slides. The blank
paraffin blocks were then punched with a precision instru-
ment (SuperBioChips Laboratory, South Korea), to make
2 mm × 60 holes; we then punched out the marked area
of donor blocks, and filled in the holes of the recipient
block. In this way, triplicate tissue cores, with diameters of
2 mm, were punched and arrayed on a recipient paraffin
block. A layer of paraffin was coated to complete an array
block with tightening of the paraffin. Then arrayed paraf-
fin blocks were cut into 4-µm sections and placed on
silane coated slides (MUTO pure chemicals, Tokyo,
Japan). Sections from the paraffin-embedded tissue were
deparaffinized, treated with 1% H2O2 in phosphate-buff-
ered saline, and submitted for antigen retrieval by micro-
wave oven treatment for 15 minutes in 0.01 mmol/L
citrate buffers at pH 6.0. The slides were subsequently
incubated in 10% normal horse serum for 30 minutes,
followed by overnight incubation, at 4°C, with appropri-
ately diluted rabbit polyclonal IgG antibodies to neogenin
as a primary antibody and the horse radish peroxidase
conjugated goat anti-rabbit IgG antibody as a secondary
antibody. Fixation control was not used. Antibodies were
the same as those used for the Western blot analysis, and
diamino-benzidine (DAB) was used as a chromogen.
Statistical analysis
Fisher's exact test from the SAS statistical software Version
8 program (SAS Institute Inc., Cary, NC) was used for sta-
tistical calculation. All statistical analyses were two-tailed.
We confirmed that all statistical results were reproducible
with SPSS Version 11.5 (SPSS Inc., Chicago, IL).
Results
As a result of the Western blot analysis from the three cell
lines, the data showed that the expression of neogenin
was strongest in the nontumorigenic M13SV1 cells. Con-
versely, in the highly tumorigenic M13SV1R2N1 cells,
neogenin was found to be only weakly expressed (Fig. 1).
Western blot analysis of paired normal and IDC tissues
from eight patients with breast cancer showed that the
strength of expression of neogenin in normal tissue varied
in each patient. However, there was a tendency toward
higher expression of neogenin in normal tissues com-
pared to the IDC tissues; this was clearly observed in 6 of
8 paired samples (Fig. 2).
Tissue array analysis was performed on 54 diverse human
breast tissue samples with different histologic diagnoses
(Table 1). The expression levels were measured, by a sin-
gle blinded senior pathologist, based on the number of
positive cells and the staining intensity; there were four
categories: none, weak, moderate and strong, used for
classification (Fig. 3). In concordance with the results of
Western blot analysis, all of the normal breast tissues
showed strong neogenin expression, while 93.5% (43/46)
of breast cancer tissues showed no neogenin expression or
only moderate levels. In 31 IDC cases, five (16.1%) did
not have any neogenin expression, fourteen (45.2%)
showed weak expression, ten (32.3%) showed moderate
expression, and only two (6.5%) had strong levels of neo-
genin expression. There was a significant difference (p <
0.001) in the expression level of neogenin in normal com-
pared to IDC cases.
Discussion
The results of the present study suggest that the expression
of neogenin may be inversely related to the tumorigenic-
ity of human breast cancer. In the Western blot analysis,
neogenin expression is noted to be strong in nontumori-
genic M13SV1 cells and decreased as the tumorigenicity
increased; neogenin expression was weakest in the highly
tumorigenic M13SV1R2N1 cells. The paired Western blot
analysis from normal and IDC tissues in eight patients
also resulted in an inverse pattern of neogenin expression
with cancer. In the tissue array, all of the normal breast tis-
sues showed a strong neogenin expression, while most
cancer tissues showed weaker neogenin expression com-
pared to normal tissues. These results suggest that the loss
of neogenin expression might be important in mammary
carcinogenesis.
Human mammary glands begin to develop with the prim-
itive mammary epithelial cells growing into epithelium
during the sixth week of fetal life. During the first three
The Western blot analyses of M13SV1, M13SV1R2 and  M13SV1R2N1 cells Figure 1
The Western blot analyses of M13SV1, M13SV1R2 and 
M13SV1R2N1 cells. The expression of neogenin is strong in 
nontumorigenic M13SV1 cells while it is weak in highly tum-
origenic M13SV1R2N1 cells. Detection is performed with 
the ECL Plex fluorescent Western blotting system (Amer-
sham, Buckinghamshire, UK).
Neogenin 
Beta-actin 
M13SV1 M13SV1R2 M13SV1R2N1BMC Cancer 2005, 5:154 http://www.biomedcentral.com/1471-2407/5/154
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weeks of human life, the rudimentary mammary duct
consists of a single duct gradually extending from the nip-
ple. By the fifth week of age, the ducts fill approximately
two-thirds of the fat pad, with a highly branched system
that exhibits second and third order branching [14]. The
terminal end bud (TEB) is the enlarged termini of ducts; a
single layer of cap cells covers the tip of the end bud. TEBs
are responsible for prodigious pubertal growth of cap cells
and underlying preluminal epithelium. Cap cells have
been suggested as mammary stem cells for ductal mor-
phogenesis [7] or as cells serving as precursors to myoep-
ithelial cells [8]. During puberty, the cap cells begin to
grow into the adjacent fatty tissue and the parenchyma
gains more fatty tissue and vessels. The accurate approxi-
mation of cap cells and preluminal epithelial cell layers is
thought to be important for mammary morphogenesis;
netrin-1 and neogenin play an important role in main-
taining this approximation. The loss of neogenin during
murine mammary morphogenesis results in widening of
the subcapsular space; this anatomical detachment causes
dissociation of the cap cells, and increased spillage of cap
cells into the preluminal compartment. This may contrib-
ute to susceptibility for the development of human breast
cancer [9,15].
Although a previous study reported that neogenin was
expressed in breast cancer cell lines, and suggested that
neogenin is not likely to be frequently affected in cancer,
this study lacked important data at the translational level
for the expression of neogenin in normal and breast can-
cer tissues [1]. Consistent with previous reports, neogenin
was expressed in breast cancer cell lines in the present
study. Moreover, we identified that there was a difference
in the expression level of neogenin based on the tumori-
genicity; this was observed as a result of experiments with
three cell lines that have the same origin as the type I
HBECs but different tumorigenicity. In the Western blot
analysis for paired specimens, neogenin showed stronger
expression in normal tissues than in each of the paired
cancer samples.
It was difficult to determine the exact intensity of neo-
genin expression in tissue arrays with anti-neogenin poly-
clonal antibody. We could not find any commercial
monoclonal anti-neogenin antibody, only polyclonal
antibody. Future experiments with more specific mono-
clonal antibodies will be required for the precise demon-
stration of neogenin expression in tissues by
immunohistochemical stain.
Conclusion
In summary, neogenin may play a role in mammary car-
cinogenesis as well as in mammary morphogenesis, and
the expression of neogenin may be inversely correlated to
mammary carcinogenicity. Further investigation is needed
to identify the value of neogenin as a potential prognostic
factor.
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Table 1: The distribution of neogenin expression according to the histology in the tissue array
Histology Expression level of neogenin Total
None Weak Moderate Strong
Normal 0 0 0 8 8
Ductal carcinoma in situ 0 0 1 0 1
Infiltrating ductal carcinoma 5 14 10 2 31
Metastatic lymph node 2 3 4 0 9
Others* 0 1 3 1 5
Total 7 18 18 11 54
*Others consist of 3 cases of invasive lobular carcinoma, 1 medullary carcinoma and 1 signet ring cell carcinoma.
Western blot analyses of paired normal and cancer tissues  from eight patients with infiltrating ductal carcinoma Figure 2
Western blot analyses of paired normal and cancer tissues 
from eight patients with infiltrating ductal carcinoma. There 
is a tendency toward higher neogenin expression in normal 
tissues compared to the IDC tissues; this is clear in samples 
1–4, 6 and 8. Detection is performed with the ECL Plex fluo-
rescent Western blotting system (Amersham, Buckingham-
shire, UK).
Neogenin 
Beta-actin 
N    C N    C N    C N    C N    C N    C N    C N    C
1                2                3               4              5                6               7                8 BMC Cancer 2005, 5:154 http://www.biomedcentral.com/1471-2407/5/154
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